SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Regis Duvignau — Reuters

145

Bristol-Myers Squibb

BMY

The biopharmaceutical company manufactures medicines for Alzheimer’s, dementia, pyschiatric disorders, cardiovascular, diabetes, oncology, and hepatitis.

Looking for leads, investment insights, or competitive intelligence?

CEO

Giovanni Caforio

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New York City

Years on Fortune 500 List

24

Employees

23,700

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$20,7766.9%
Profits ($M)$1,007.0-77.4%
Assets ($M)$33,551
Total Stockholder Equity ($M)$11,741
Market Value — as of March 29, 2018 ($M)$103,415
Profit Ratios
Profit as % of Revenues4.8%
Profits as % of Assets3.0%
Profits as % of Stockholder Equity8.6%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)0.61
EPS % Change (from 2016)-77.0%
EPS % Change (5 year annual rate)-12.1%
EPS % Change (10 year annual rate)-5.6%
Total Return
Total Return to Investors (2017)7.8%
Total Return to Investors (5 year, annualized)16.6%
Total Return to Investors (10 year, annualized)13.0%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Bristol-Myers Squibb

Russian Drugmaker Granted License to Produce Celgene Copycat

Russian drugmaker Nativa got a compulsory license to produce a cheaper version of Celgene's Revlimid.

Read More →
A Cancer Blockbuster Gets Approved in China. Will the Floodgates Now Open?

Chinese drug regulators gave the nod to Bristol-Myers Squibb’s immune therapy star Opdivo. Dozens of companies are hoping they’re next.

Read More →
Merck's Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half.

Read More →
Why Cancer Drug Maker Incyte's Stock Plunged—And Took Others Down With It

Drug giants Merck and Bristol-Myers Squibb felt the pain, too.

Read More →